Post job

Novo Nordisk CEO and executives

Executive Summary. Based on our data team's research, Lars Fruergaard Jørgensen is the Novo Nordisk's CEO. Novo Nordisk has 42,682 employees, of which 55 are in a leadership position.
Here are further demographic highlights of the leadership team:
  • The Novo Nordisk executive team is 42% female and 58% male.
  • 70% of the management team is White.
  • 9% of Novo Nordisk management is Hispanic or Latino.
  • 12% of the management team is Black or African American.
Work at Novo Nordisk?
Share your experience

Rate Novo Nordisk's leadership communication with employees.

Zippia waving zebra
Name & TitleBio
Lars Fruergaard Jørgensen

President and Chief Executive Officer (CEO)

Lars Fruergaard Jørgensen's LinkedIn

Lars Fruergaard Jørgensen joined Novo Nordisk in 1991 as an economist in Health Care, Economy & Planning and has over the years completed overseas postings in the Netherlands, the US and Japan. In 2004 he was appointed senior vice president for IT & Corporate Development. In January 2013 he was appointed executive vice president and chief information officer assuming responsibility for IT, Quality & Corporate Development. In November 2014 he took over the responsibilities for Corporate People & Organisation and Business Assurance and became chief of staff. Mr Jørgensen was appointed president and chief executive officer in January 2017.

Mr Jørgensen serves as vice-chair of the supervisory board and member of the nomination committee of Carlsberg A/S.

Mr Jørgensen has an MSc in Finance and Business Administration from Aarhus School of Business, Aarhus University, Denmark, from 1991.

Mr Jørgensen is a Danish national, born November 1966.

Ludovic Helfgott

Executive Vice President and Head of Rare Disease

Ludovic Helfgott's LinkedIn

Martin Holst Lange

Executive Vice President, Head of Development

Martin Holst Lange's LinkedIn

Doug Langa

Executive Vice President and Head of North America Operations

Doug Langa's LinkedIn

Karsten Munk Knudsen

Executive Vice President and Chief Financial Officer

Karsten Munk Knudsen's LinkedIn

Karsten Munk Knudsen joined Novo Nordisk in 1999 as a business analyst in NNIT A/S, previously a subsidiary of Novo Nordisk, and has since held finance positions of growing size and complexity throughout the Novo Nordisk value chain. From 2010 to 2014 Mr Knudsen was corporate vice president for Finance & IT at Novo Nordisk Inc. in the US and in 2014 he was appointed senior vice president of Corporate Finance in Novo Nordisk. In February 2018 Mr Knudsen was promoted to executive vice president and chief financial officer. In April 2019 Mr Knudsen assumed further responsibilities as his area was expanded to cover Finance, Legal & Procurement.

Mr Knudsen serves as chair of the board of NNE A/S, Denmark.

Marcus Schindler

Executive Vice President For Research & Early Development and Chief Scientific Officer

Marcus Schindler's LinkedIn

My team and I identify creative, innovative and differentiated science, technology platforms and compounds, build productive collaborations based on mutual respect and trust and also bring strategically relevant external innovation into Novo Nordisk’s R&D organisation- for the benefit of people with diabetes, obesity, cardiovascular diseases and NASH

Camilla Sylvest

Executive Vice President and Head of Commercial Strategy & Corporate Affairs

Camilla Sylvest's LinkedIn

Henrik Ehlers Wulff

Executive VP & Head-Information Technology

Henrik Ehlers Wulff's LinkedIn

Maziar Mike Doustdar

Executive Vice President and Head of International Operations

Maziar Mike Doustdar's LinkedIn

Monique Carter

Executive Vice President and Head of People & Organisation

Monique Carter's LinkedIn

Do you work at Novo Nordisk?

Does leadership effectively guide Novo Nordisk toward its goals?

Novo Nordisk jobs

Novo Nordisk board members

Name & TitleBio
Andreas Fibig

Board Member

Anna Frable

Vice President

Elisabeth Dahl Christensen

Board Member

Elisabeth Dahl Christensen's LinkedIn

Helge Lund

Chair of The Board

Henrik Poulsen

Board Member

Henrik Poulsen's LinkedIn

Jeppe Fonager Christiansen

Board Member

Jeppe Fonager Christiansen's LinkedIn

Kasim Kutay

Board Member

Kasim Kutay's LinkedIn

Laurence Debroux

Board Member

Laurence Debroux's LinkedIn

Liselotte Hyveled

Board Member

Liselotte Hyveled's LinkedIn

Mette Bøjer Jensen

Board Member

Mette Bøjer Jensen's LinkedIn

Novo Nordisk leadership demographics

Novo Nordisk gender distribution in management team

  • The Novo Nordisk executive team is 42% female and 58% male.
  • Novo Nordisk is 51% female and 49% male company-wide.
Male
Male
58%
Company-wide: 49%
Female
Female
42%
Company-wide: 51%

Novo Nordisk executives by race

Management Team:
  • The most common ethnicity among Novo Nordisk executive officers is White.
  • 70% of the management team is White.
  • 12% of Novo Nordisk's management is Black or African American.
  • 9% of the management team is Hispanic or Latino.
Company-wide:
  • White is the most common ethnicity company-wide.
  • 58% of employees are White.
  • 13% of employees are Hispanic or Latino.
  • 12% of employees are Asian.
  • Management team
  • General
100%
80%
60%
40%
20%
0%
Unknown
White
Black or African American
Asian
Hispanic or Latino

Novo Nordisk jobs nearby

Novo Nordisk executives FAQs

Zippia gives an in-depth look into the details of Novo Nordisk, including salaries, political affiliations, employee data, and more, in order to inform job seekers about Novo Nordisk. The employee data is based on information from people who have self-reported their past or current employments at Novo Nordisk. The data on this page is also based on data sources collected from public and open data sources on the Internet and other locations, as well as proprietary data we licensed from other companies. Sources of data may include, but are not limited to, the BLS, company filings, estimates based on those filings, H1B filings, and other public and private datasets. While we have made attempts to ensure that the information displayed are correct, Zippia is not responsible for any errors or omissions or for the results obtained from the use of this information. None of the information on this page has been provided or approved by Novo Nordisk. The data presented on this page does not represent the view of Novo Nordisk and its employees or that of Zippia.

Novo Nordisk may also be known as or be related to Novo Nordisk, Novo Nordisk Inc, Novo Nordisk Inc., Novo Nordisk Pharmaceuticals Inc and Novo Nordisk, Inc.